Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 4/20 | 0.42 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | CHAT | P28329 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.38 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16152184 | 1.00 | POLB (0.42) | POLBCA2DTYMKTRPM2ENPP1 | |
| SCHEMBL13552123 | 0.92 | POLB (0.44) | POLBCA2DTYMKTRPM2ENPP1 | |
| SCHEMBL16152183 | 0.90 | POLB (0.46) | POLBCA2DTYMKTRPM2ENPP1 | |
| SCHEMBL20417316 | 0.90 | POLB (0.42) | POLBCA2DTYMKTRPM2ENPP1 | |
| SCHEMBL20417307 | 0.90 | POLB (0.42) | POLBCA2DTYMKTRPM2ENPP1 | |
| SCHEMBL13654807 | 0.87 | POLB (0.45) | POLBCA2DTYMKTRPM2ENPP1 | |
| SCHEMBL13554340 | 0.85 | POLB (0.45) | POLBDTYMKTRPM2ENPP1P2RY1 | |
| SCHEMBL16152145 | 0.85 | POLB (0.45) | POLBDTYMKTRPM2ENPP1P2RY1 | |
| SCHEMBL24970387 | 0.84 | CA2 (0.40) | POLBCA2DTYMKP2RX1P2RX3 | |
| SCHEMBL22327013 | 0.83 | ENTPD1 (0.38) | POLBCA2DTYMKP2RY1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270210-A1 | METHOD AND REAGENT FOR GENE SEQUENCE ANALYSIS | HITACHI, LTD. (JP) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270210-A1 | METHOD AND REAGENT FOR GENE SEQUENCE ANALYSIS | RNGTT, DNTT, MTAP | POLB 56/4885CA2 3991/4885DTYMK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.